PDT Partners LLC Invests $3.97 Million in Dynavax Technologies Co. (NASDAQ:DVAX)

PDT Partners LLC acquired a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 356,115 shares of the biopharmaceutical company’s stock, valued at approximately $3,967,000.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Dynavax Technologies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock valued at $116,682,000 after buying an additional 126,458 shares during the period. Renaissance Technologies LLC raised its position in shares of Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after acquiring an additional 53,600 shares in the last quarter. Great Point Partners LLC lifted its stake in shares of Dynavax Technologies by 87.7% in the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 1,109,080 shares during the period. Millennium Management LLC bought a new stake in shares of Dynavax Technologies during the 2nd quarter valued at about $17,615,000. Finally, Mizuho Markets Americas LLC grew its stake in Dynavax Technologies by 17.4% during the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after purchasing an additional 204,475 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $12.86 on Friday. The business has a 50-day simple moving average of $11.65 and a 200 day simple moving average of $11.38. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $15.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of 98.92 and a beta of 1.34.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on DVAX shares. The Goldman Sachs Group dropped their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.